These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35630016)

  • 1. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.
    Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
    Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
    Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
    Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis.
    Rizzo A; Cusmai A; Massafra R; Bove S; Comes MC; Fanizzi A; Rinaldi L; Acquafredda S; Gadaleta-Caldarola G; Oreste D; Zito A; Giotta F; Lorusso V; Palmiotti G
    Cells; 2022 Jun; 11(12):. PubMed ID: 35740985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoimmunotherapy in early triple-negative breast cancer: a new kid on the block?
    Rizzo A; Palmiotti G
    Immunotherapy; 2022 Jul; 14(10):755-758. PubMed ID: 35642433
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
    Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
    Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
    O'Rourke H; Hart C; De Boer RH
    Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
    Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
    Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Mohamed A; Kruse M; Tran J
    Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in Triple-Negative Breast Cancer.
    Emens LA
    Cancer J; 2021 Jan-Feb 01; 27(1):59-66. PubMed ID: 33475294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
    Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
    N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
    Tarantino P; Gandini S; Trapani D; Criscitiello C; Curigliano G
    Crit Rev Oncol Hematol; 2021 Mar; 159():103223. PubMed ID: 33482345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
    Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
    Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis.
    Rizzo A; Schipilliti FM; Di Costanzo F; Acquafredda S; Arpino G; Puglisi F; Del Mastro L; Montemurro F; De Laurentiis M; Giuliano M
    ESMO Open; 2023 Dec; 8(6):102198. PubMed ID: 38100933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?
    Giugliano F; Valenza C; Tarantino P; Curigliano G
    Expert Opin Investig Drugs; 2022 Aug; 31(8):855-874. PubMed ID: 35762248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy and breast cancer: an overview.
    Mezni E; Behi K; Gonçalves A
    Curr Opin Oncol; 2022 Sep; 34(5):587-594. PubMed ID: 35838204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How shall we treat locally advanced triple negative breast cancer?
    Luz P; Dias D; Fortuna A; Bretes L; Gosalbez B
    F1000Res; 2019; 8():1649. PubMed ID: 32802311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.
    Davis AA; Gradishar WJ
    Oncology (Williston Park); 2020 May; 34(5):176-182. PubMed ID: 32644178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.